이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Landfar Bio-medicine 관리

관리 기준 확인 0/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Changqiao You

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	2.6yrs
CEO 소유권	n/a
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	2.6yrs

최근 관리 업데이트

Recent updates

Risks Still Elevated At These Prices As Landfar Bio-medicine Co., Ltd (SZSE:000504) Shares Dive 31%

Jun 09

Landfar Bio-medicine Co., Ltd's (SZSE:000504) Popularity With Investors Under Threat As Stock Sinks 32%

Apr 17

Landfar Bio-medicine Co., Ltd (SZSE:000504) Investors Are Less Pessimistic Than Expected

Mar 01

CEO

Changqiao You (51 yo)

2.6yrs

테뉴어

CN¥1,858,800

보상

Mr. Changqiao You is GM & Director of Landfar Bio-medicine Co., Ltd.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Changqiao You	GM & Director	2.6yrs	CN¥1.86m	데이터 없음
Weihua Cu	Independent Director	5.9yrs	CN¥96.00k	데이터 없음
Yuan Chen	Director	2.6yrs	데이터 없음	데이터 없음
Chen Shen	Supervisor	5.9yrs	데이터 없음	데이터 없음
Yun Yang	Chairman	2.6yrs	CN¥1.05m	데이터 없음
Haiyi Cao	Director	2.6yrs	데이터 없음	데이터 없음
Yaqing Zhao	Independent Director	2.6yrs	CN¥96.00k	데이터 없음
Ping Zhao	Independent Director	2.6yrs	CN¥96.00k	데이터 없음
Jian Qiu	Chairman of the Supervisory Board	2.6yrs	데이터 없음	데이터 없음
Feng Yan	Employee Representative Supervisor	2.3yrs	데이터 없음	데이터 없음

2.6yrs

평균 재임 기간

44.5yo

평균 연령

경험이 풍부한 이사회: 000504 의 이사회는 경험(평균 재직 기간 2.5 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

Landfar Bio-medicine 관리

관리 기준 확인 0/4

주요 정보

최근 관리 업데이트

Landfar Bio-medicine Co., Ltd, Annual General Meeting, May 24, 2024

Less than half of directors are independent

NanHua Bio-medicine Co., Ltd, Annual General Meeting, May 25, 2022

Recent updates

Landfar Bio-medicine Co., Ltd to Report First Half, 2024 Results on Aug 31, 2024

Risks Still Elevated At These Prices As Landfar Bio-medicine Co., Ltd (SZSE:000504) Shares Dive 31%

First quarter 2024 earnings released: CN¥0.008 loss per share (vs CN¥0.006 loss in 1Q 2023)

Landfar Bio-medicine Co., Ltd, Annual General Meeting, May 24, 2024

Landfar Bio-medicine Co., Ltd's (SZSE:000504) Popularity With Investors Under Threat As Stock Sinks 32%

Chongqing International Trust Co., Ltd. acquired 10.8% stake in Landfar Bio-medicine Co., Ltd (SZSE:000504) from Shanghai Heping Dazong Equity Investment Fund Management Co., Ltd for CNY 0.03 million.

Landfar Bio-medicine Co., Ltd to Report Q1, 2024 Results on Apr 30, 2024

Landfar Bio-medicine Co., Ltd (SZSE:000504) Investors Are Less Pessimistic Than Expected

Less than half of directors are independent

Landfar Bio-medicine Co., Ltd to Report Fiscal Year 2023 Results on Apr 30, 2024

Third quarter 2023 earnings released: EPS: CN¥0.033 (vs CN¥0.005 loss in 3Q 2022)

Second quarter 2023 earnings released: CN¥0.023 loss per share (vs CN¥0.007 profit in 2Q 2022)

New minor risk - Share price stability

Now 22% undervalued after recent price drop

Full year 2022 earnings released: CN¥0.04 loss per share (vs CN¥0.06 loss in FY 2021)

Third quarter 2022 earnings released: CN¥0.005 loss per share (vs CN¥0.007 loss in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.007 (vs CN¥0.023 loss in 2Q 2021)

NanHua Bio-medicine Co., Ltd, Annual General Meeting, May 25, 2022

First quarter 2022 earnings released: EPS: CN¥0.001 (vs CN¥0.003 in 1Q 2021)

Third quarter 2021 earnings released: CN¥0.007 loss per share (vs CN¥0.004 loss in 3Q 2020)

Second quarter 2021 earnings released: CN¥0.023 loss per share (vs CN¥0.002 loss in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.003 (vs CN¥0.005 loss in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.03 (vs CN¥0.06 in FY 2019)

NanHua Bio-medicine Co., Ltd to Report Fiscal Year 2020 Results on Mar 31, 2021

New 90-day high: CN¥13.58

New 90-day low: CN¥9.82

New 90-day low: CN¥12.15

New 90-day low: CN¥12.42

NanHua Bio-medicine Co., Ltd to Report Q3, 2020 Results on Oct 26, 2020

New 90-day high - CN¥14.24

NanHua Bio-medicine Co., Ltd to Report First Half, 2020 Results on Aug 28, 2020

CEO

테뉴어

보상

이사회 구성원

평균 재임 기간

평균 연령